Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured

Aptevo Therapeutics Inc.

Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.
RAINIER trial on track for completion and Phase 2 dose selection by year-end 2026.
Q1 2026 cash position $14.5M; raised $0.9M net under SEPAs; secured new $60M SEPA with Yorkville.
Jeff Lamothe appointed CEO; Marvin White transitions to Executive Chair.
Leadership believes the $60M facility extends capital access into 2029 through key catalysts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aptevo Therapeutics Inc. reported preliminary financial results for the period ended March 31, 2026.

Period: the period ended March 31, 2026
Result: preliminary results

Exact text from the filing

On May 13, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.